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Purpose: To explore possible genetic aberrations in a Chinese family with aniridia, ptosis and mental retardation,
and provide genetic evidence for the prenatal diagnosis.
Methods: 14 exons of PAX6 in the proband were sequenced by the Sanger sequencing technique. Multiplex
ligation-dependent probe amplification (MLPA) technique was employed to further explore gene alterations
of PAX6. Single nucleotide polymorphisms-array (SNP-array) assay was applied to screen potential pathologic
genome-wide copy number variations (CNV).
Results: There were no detectable pathogenic mutations in the 14 exons of PAX6 in the proband. MLPA indicated
a heterozygous deletion encompassing all PAX6 gene regions covered and a partial upstream region. SNP-array
assay detected a heterozygous 11p13 microdeletion with a length of 518 kb in the proband, spanning two whole
annotated genes, elongation factor protein 4 (ELP4), the paired box gene 6 (PAX6), and partial IMP1 inner-mitochondrial
membrane (IMMP1L) gene. SNP-array revealed her affected brother carried the identical deletion.
Conclusions: The 518 kb heterozygous deletion in 11p13 encompassing PAX6 should be the genetic etiology for the
familial aniridia.
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Congenital aniridia (OMIM 106210) is a kind of eye
disorder characterized by complete or partial hypoplasia
of the iris. The worldwide prevalence of aniridia was
estimated to be 1:50 000 to 1:100 000 in the year of 2013
[1]. About two-thirds of reported aniridia cases were
familial and showed a dominant inheritance manner with
nearly complete penetrance, the remaining one-third were
sporadic [2]. PAX6 (OMIM 607108), a well-known aniri-
dia disease-causing gene located in chromosome 11p13
region, contains 14 exons and encodes a protein of 422
amino acids. As a transcriptional factor, PAX6 is involved
in the development of a diversity of tissues and organs* Correspondence: njxzf@126.com
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unless otherwise stated.including ocular tissues, olfactory bulb, neural tube, gut
and pancreas [3,4]. Heterozygous loss of function of PAX6
was identified in about 90% aniridia cases, with intragenic
mutations accounting for approximately two-thirds of
cases and chromosomal rearrangements accounting for
the other one-third [2].
Previous studies demonstrated that people harboring
PAX6 mutation displayed a clinical symptom spectrum
including aniridia, corneal opacification, keratitis, cataract,
glaucoma, lens dislocation, ciliary body hypoplasia, foveal
hypoplasia, strabismus, nystagmus, Peter’s anomaly, optic
nerve defects [5], hyposmia, abnormal inter-hemispheric
auditory transfer [6], impaired islet function [7] and brain
structure abnormalities [8]. Until now, approximately 357
intragenic mutations have been documented in the PAX6
mutation database (http://www.hgu.mrc.ac.uk/Softdata/
PAX6/), while microdeletion cases associated with PAX6
region were rare.s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion including PAX6 in a small Chinese family with aniridia,
cataract, ptosis and mental retardation detected by SNP-
array assay.
Case presentation
This three-generation family included four affected
patients, two of them were available for this study
(Figure 1A).
The proband (II:1), a 31-years-old pregnant Chinese Han
female who suffered from congenital bilateral completeFigure 1 11p13 microdeletion in the family with aniridia. A. Pedigree
respectively. The symbols in black represent the affected members. The arr
individual. The inheritance pattern in the family is autosomal dominant. B.
filled with solid blue represent probes that display nearly half dose reduced
identified by SNP-array. This deletion harbors two whole genes ELP4, PAX6absence of iris, cataracts, bilateral ptosis was referred to
our center for genetic counseling at 7 weeks' gestation. She
is the first child born to a non-consanguineous couple. Her
father is healthy while her mother (I:1) and bother were
suffered by anirida. She is normal in growth and speaking
during her development. She did not display any intellec-
tual disability. Her first child, who was also affected by
anirida, was born when she was 24. Her mother and first
child deceased at the age of 45 and 5 due to non-medically
related causes. Serum growth hormone (GH), thyroid
stimulating hormone (TSH), free triiodothyronine (fT3),of the family. Squares and circles indicated males and females
ow indicates the proband. The square with a line indicated a deceased
MLPA results from a normal control and the proband (II:1). These peaks
. C. The 518 kb genomic microdeletion of chromosome 11p13
, and the first two exons of IMMP1L.
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range. Ultrasonography results indicated her internal
organs were normal.
Her affected brother (II:2) of 26-years-old was also
recruited for clinical tests. He is normal in height and
weight. Physical examination was normal, while minor
anomalies including prominent forehead, short philtrum
were observed. He was diagnosed with mental retardation
when he was 7 years-old. His IQ was 70 when he was
17 years-old. Ultrasonography results indicated his internal
organs were normal. MRI did not reveal any structure
abnormalty.
Results
Mutation analysis for PAX6
Mutation screening of 14 PAX6 exons by Sanger sequen-
cing did not reveal any abnormality in the proband (data
not shown).
Multiple ligation-dependent probe amplification (MLPA)
assays
MLPA assays were used to identify possible PAX6 micro-
deletion (Figure 1B). MLPA results revealed that the
height of all these probes in the ELP4 and PAX6 displayed
nearly half-dose reduced, whereas probes targeting genes
up- or downstream to the deletion such as DCDC1,
RCN1,WT1, exhibited nearly the same height as the nor-
mal. MLPA assay on amniotic fluid cells collected at the
18 gestation week revealed the fetus (III:2) did not inherit
the deletion from the mother. The female baby was born
at 39 weeks, and physical examinations confirmed no
abnormalities especially in the eyes. Due to the unavail-
ability of the DNA samples, we are unable to determine
whether the deletion existed in patients (I:2, III:1).
SNP-array assay
SNP-array test was applied to find possible pathologic
copy number variations besides PAX6 microdeletion in
the proband and her brother. The results identified a
heterozygous deletion in the 11p13 region expanding
from 31,486,211 to 32,004,859 bp (hg18) with a length
of 518Kb in the proband. The deleted genomic fragment
contains two whole genes, elongation factor protein 4
(ELP4), the paired box gene 6 (PAX6), and partial IMP1
inner-mitochondrial membrane (IMMP1L) gene (exon1, 2).
Additionally, an identical 11p13 deletion was identified in
proband’s brother (Figure 1C). However, no other patho-
logic copy number variations were found in the genome-
wide SNP-array scanning in both of them.
Discussion
In this study, we characterized a novel 518 kb deletion
on 11p13 in a three-generation Chinese Han family with
familial aniridia. In addition to the aniridia and cataracts,interestingly, one of them also presented with mental
retardation. We speculated that PAX6, which lies in the
deleted region, primarily accounted for these clinical
features.
Neurological disorders such as mental retardation [9],
autism [10], epilepsy, cognitive impairments or behavioral
abnormalities [11] are uncommon in individuals with
PAX6 mutations. Chromosome microdeletions were much
less commonly reported in aniridia patients than PAX6
point mutations. As far as we know, only 14 cases were
found to carry genomic microdeletion encompassing
PAX6 or its regulatory region but notWT1 to date [12-20],
and only one of them displayed neurodevelopmental disor-
ders. Davis LK et al. reported a 13-year-old patient with
aniridia, autism, and mental retardation carrying a 1.3 Mb
heterozygous microdeletion, approximately 35 kb distal to
the last exon of PAX6 [15]. Further study indicated the
deletion was inherited from the mother who presented with
aniridia, depression, anxiety, and social awkwardness.
Though the copy number of PAX6 was intact in the
family, the regulatory genomic region of PAX6 nearby
ELP4 included in the deletion was believed to be the
etiology. In our study, a 518 kb submicroscopic deletion
including PAX6, ELP4 and partial IMMP1L was identi-
fied. All the four patients in the family were normal in
other physical development, but the proband’s brother
presented with moderate mental retardation, indicating
a marked intra-familial variation.
Neurological disorders presented in individuals with
PAX6 mutations can be explained by the PAX6 expression
pattern and outcome from animal model research. PAX6
expressed in the telencephalon, diencephalon, caudal
rhombencephalon, myelencephalon and spinal cord, but
not mesencephalon in the embryonic period, and adult
brains [21-23], suggesting a role in the brain development.
Pax6 mutant mice/rats displayed abnormal development
in arealisation of the cerebral cortex, formation of the
prosencephalon-mesencephalon boundary, axon guidance,
differentiation of neurons from glia and neuronal migra-
tion in the cerebellum [24]. Brain defects were occasion-
ally found to be related with PAX6 mutations. Magnetic
resonance imaging (MRI) examination on patients with
PAX6 mutations revealed a spectrum of brain abnormal-
ities including absence/hypoplasia of the anterior commis-
sure, reduced olfaction [25], polymicrogyria, absence of
pineal gland [8], reduction in the white matter in the cor-
pus callosum and grey matter in the anterior cingulated
cortex, cerebellum, medial temporal lobe [26]. However,
the patients’ brains were normal detected by brain MRI
test in our case. The detailed molecular mechanisms
underlying the mental retardation and brain structure
defects of PAX6 mutation is yet unknown.
Congenital aniridia can also occur in the WAGR syn-
drome (Wilms’ tumor, aniridia, genitourinary abnormalities,
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gene deletion encompassing both PAX6 and WT1. Individ-
uals, particularly children under 6 years old, with WT1
deletion may predispose to Wilms’ tumor, a kidney tumor
with childhood onset [13]. Defining the accurate break-
points of the 11p13 deletion may contribute to the genetic
counseling, disease prognosis and prevention [1].
Another interesting gene is EPL4, which encodes a
component of the six subunit elongator complex, a histone
acetyltransferase complex that associates directly with the
RNA polymerase II (Pol II) holoenzyme involved in tran-
scriptional elongation. DNaseI hypersensitivity mapping
and reporter transgenic assays revealed the presence of
several putative cis-regulatory elements, including ones
driving expression in lens and retina [27]. These elements
reside within introns of the adjacent, ubiquitously
expressed ELP4 gene, but are nevertheless thought to
be PAX6-specific long-range control elements [28].
Andrea C et al. demonstrated that three SNPs in ELP4
affect the size of the optic nerve head [29]. Zhang X et al.
revealed that a 3' deletion to the PAX6 gene including the
ELP4 was identified in one three-generation family with
total aniridia [19]. A part of IMMP1L gene was also
deleted in our patients. IMMP1L encode a subunit of
IMP (mitochondrial inner membrane peptidase) com-
plex which plays a role in the generating mature, active
proteins in the mitochondrial intermembrane space by
proteolytically removing the mitochondrial targeting
presequence of nuclear-encoded proteins.
In this study, we accurately identified the pathologic
genetic aberration of the family using SNP-array. In fact,
consistent with our prenatal genetic diagnosis assistance,
they delivered a healthy baby. The couple was informed
they have a 50% chance to birth a healthy baby in subse-
quent pregnancies.
Conclusions
In summary, this study identified a novel deletion contain-
ing PAX6 in a Chinese family, expanding the mutation
spectrum of PAX6 aberration. The 518 kb heterozygous
deletion of chromosome 11p13 may be the cause of the
familial aniridia, congenital ptosis and slight mental retard-
ation in this family. The function of the deleted genes are
needed to be further studied. This work emphasizes the
necessity to screen for possible microdeletion related with
PAX6 in patients with aniridia particularly when result of
conventional sequencing analysis for PAX6 is negative.
Methods
DNA extraction and sequencing
Genomic DNA was extracted from the venous blood of
the two adult patients and cultured amniotic fluid fibro-
blasts. The 14 exons of PAX6 gene were amplified by
polymerase chain reaction (PCR) using primers describedby Redeker, et al. [10]. Obtained PCR products were
sequenced bi-directionally using the ABI BigDye Termin-
ator Cycle Sequencing kit v3.1 (ABI Applied Biosystems,
Foster City, CA), according to the standard protocol.
SNP-array assay
Human cyto12 SNP-array (Illumina, USA) comprising
around 300,000 SNPs was applied for whole genome scan
on the two affected individuals (the proband II-1 and her
brother II-3). SNP-array tests were performed according
to the manufacturer's protocol (Illumina, USA), chromo-
some karyotype analysis was carried out by KaryoStudio
V 1.3.11 (Illumina, USA) and GenomeStudio V2011.1
(Illumina, USA) respectively. We use hg18 genome coord-
inate in this study.
Multiplex ligation-dependent probe amplification (MLPA)
technique
SALSA MLPA Kit P219-B2 PAX6 (MRC-Holland
Amsterdam, Netherlands) was employed to verify the
abnormal SNP-array findings and to test the DNA of the
present fetus. The kit contains probes targeting each
exon of PAX6 with the exception of exon 7 and 13, and
multiple other genes within 11p13 region including
BDNF, FSHB, DCDC1, ELP4, RCN1, WT1, LOC645981,
LOC646008, HIPK3, LMO2, EHF, CD44 and SOX2. In
brief, 100 ng DNA samples were denatured for 5 min at
98°C and then cooled to 25°C. Probes were mixed and
hybridized with DNA samples at 60°C overnight and
were then reacted with ligase 65 at 54°C for 15 min,
followed by 5 min at 98°C and kept at 4°C. Finally, all
probes and sample ligations were amplified by PCR
using specific carboxyfluorescein (FAM) labeled PCR
primers. Electrophoresis was performed using an ABI
PRISM 3130 (Applied Biosystems) and Data was analyzed
by GeneMarker V4.0 software. A peak area ratio between
0.7 and 1.3 times was considered as normal one, below 0.7
represents deletions and above 1.3 represents duplications.
Each result was confirmed by two independent tests.
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